Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
No Data
BTCY Transcript
Biotricity, Inc. (BTCY) Q3 2026 Earnings Call Transcript
Positive2-11
The earnings call highlights strong revenue growth, improved profitability, and positive EBITDA, indicating a solid financial performance. Product development and market expansion efforts are promising, with a focus on AI and international distribution. Despite some risks, such as regulatory approvals and sales strategy, the overall sentiment is positive due to strategic initiatives and operational efficiencies. With no negative sentiment from the Q&A, the stock price is likely to increase by 2% to 8% over the next two weeks.
Biotricity, Inc. (BTCY) Q2 2026 Earnings Call Transcript
Positive11-14
The earnings call highlights strong revenue growth, improved profitability, and strategic market expansion. While there are risks, such as regulatory hurdles and market penetration challenges, the company's positive free cash flows, improved gross profit margins, and strategic partnerships contribute to a favorable outlook. The absence of negative sentiment in the Q&A session further supports a positive sentiment. Despite a net loss, the reduction in losses and positive EBITDA indicate progress towards profitability, leading to a predicted stock price movement in the 2% to 8% range over the next two weeks.
Biotricity, Inc. (BTCY) Q4 2025 Earnings Conference Call Transcript
Positive7-18
The earnings call highlights strong financial performance with a 16.5% YoY revenue increase and a significant improvement in gross margins. Operating expenses have decreased, and there is progress towards profitability with positive adjusted EBITDA in Q4. The Q&A section reveals some uncertainties, but overall, management's optimism and strategic initiatives, like international expansion and data monetization, are positive. Despite some vague timelines, the company's strong financials and strategic plans outweigh the risks, suggesting a positive stock price movement.
Biotricity, Inc. (BTCY) Q2 2025 Earnings Call Transcript
Neutral11-16
BTCY Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
